California-based AI preclinical experiments company VeriSIM Life has acquired Spanish AI drug discovery company Molomics Biotech for an undisclosed amount. Other terms and financial details of the transaction have also not been disclosed.
The transaction will integrate VeriSIM’s AI drug discovery platform BIOSIM with Molomics’ AI and Human Collective Intelligence (HCI) technology, which enables the identification of flaws in AI-discovered drugs. The integration is expected to enhance the computational prediction of the clinical success of drugs, thus expediting the entire drug development process.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.